Data support continued laquinimod trials, but not in MS

8 May 2017

Israeli firm Teva Pharmaceutical Industries (NYSE: TEVA) and partner Active Biotech (NORDIC: ACTI) have announced results from a Phase III trial into laquinimod as a treatment for multiple sclerosis, which show the primary endpoint was not met.

While there were some more encouraging data for the companies on the secondary endpoints, it was not enough to prevent a slide in the Swedish firm’s share price, which lost about two thirds of its value today.

Michael Hayden, chief scientific officer at Teva, said: “We have learned a great deal from the trial and we will continue our analysis of the data.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK